Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News Alert: CMS proposes major TAVR changes

News You Need to Know Today
News Alert: CMS proposes major TAVR changes
Tuesday, June 16, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients

After months of consideration, CMS has proposed sweeping changes to its TAVR coverage policies. The agency is accepting public comments until July 15.

READ MORE >
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
Share on Twitter Share on Facebook Share on Linkedin

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients

Share on Twitter Share on Facebook Share on Linkedin
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
After months of consideration, CMS has proposed sweeping changes to its TAVR coverage policies. The agency is accepting public comments until July 15.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

FDA's warning for cath labs | Stryker to acquire IVL company | New data on resistant hypertension | More patients, fewer doctors
Fraud allegations lead to $4.75M settlement | Hospital sues cardiology practice | A new business model | Whoop raises $575M
FDA clears AI for cardiac amyloidosis | SVS works to improve vascular care | Paravalvular leak after TTVR
Week in Review: Cardiologist says he was fired for speaking out | Millions of devices recalled | Hospital sues practice
A new approval for smallest defibrillation lead of its kind | Post-TAVR bleeding | Key details about reprocessed catheter recall
Medline recalls millions of devices due to safety risk | FDA's warning about sizing catheters | Post-TAVR bleeding events
Fighting for new cath lab safety standards | FDA confirms Impella recall | ‘Practice-changing’ research | Heart failure & PCI

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …10
    • Page 11
    • Page 12
    • Page 13
    • Current page 14
    • Page 15
    • Page 16
    • Page 17
    • Page 18 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup